AAAAAA
Results:
1-7
|
Results: 7
Authors:
Kaufman, HL
DeRaffele, G
Divito, J
Horig, H
Lee, D
Panicali, D
Voulo, M
Citation: Hl. Kaufman et al., A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma, HUM GENE TH, 12(11), 2001, pp. 1459-1480
Authors:
Lieberman, SM
Horig, H
Kaufman, HL
Citation: Sm. Lieberman et al., Innovative treatments for pancreatic cancer, SURG CL NA, 81(3), 2001, pp. 715
Authors:
Kicska, GA
Long, L
Horig, H
Fairchild, C
Tyler, PC
Furneaux, RH
Schramm, VL
Kaufman, HL
Citation: Ga. Kicska et al., Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes, P NAS US, 98(8), 2001, pp. 4593-4598
Authors:
Horig, H
Wainstein, A
Long, L
Kahn, D
Soni, S
Marcus, A
Edelmann, W
Kucherlapati, R
Kaufman, HL
Citation: H. Horig et al., A new mouse model for evaluating the immunotherapy of human colorectal cancer, CANCER RES, 61(23), 2001, pp. 8520-8526
Authors:
Horig, H
Lee, DS
Conkright, W
Divito, J
Hasson, H
LaMare, M
Rivera, A
Park, D
Tine, J
Guito, K
Tsang, KWY
Schlom, J
Kaufman, HL
Citation: H. Horig et al., Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule, CANCER IMMU, 49(9), 2000, pp. 504-514
Authors:
Horig, H
Kaufman, HL
Citation: H. Horig et Hl. Kaufman, Current issues in cancer vaccine development, CLIN IMMUNO, 92(3), 1999, pp. 211-223
Authors:
Horig, H
Young, ACM
Papadopoulos, NJ
DiLorenzo, TP
Nathenson, SG
Citation: H. Horig et al., Binding of longer peptides to the H-2K(b) heterodimer is restricted to peptides extended at their C terminus: Refinement of the inherent MHC class I peptide binding criteria, J IMMUNOL, 163(8), 1999, pp. 4434-4441
Risultati:
1-7
|